Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment

Hepatology

Volumn 29, Issue 6, 1999, Pages 1870-1875

  Valla, D C ^a   Chevallier, M ^a   Marcellin, P ^a   Payen, J L ^a   Trepo, C ^a   Fonck, M ^a   Bourliere, M ^a   Boucher, E ^a   Miguet, J P ^a   Parlier, D ^a   Lemonnier, C ^a   Opolon, P ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ALPHA2B INTERFERON; BILIRUBIN; COLLAGEN; PROTHROMBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032997086     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290616     Document Type: Article

References (30)

1. 1 Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997 ; 26 (Suppl 1): 15S–20S. MEDLINE
2. 2 Roudot‐Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus‐related liver disease: a French survey of 6,664 patients. the study group for the prevalence and the epidemiology of hepatitis C virus. Hepatology 1997 ; 26: 485–490. MEDLINE
3. 3 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. for the OBSVIR, METAVIR and DOSVIR groups Lancet 1997 ; 349: 825–832. MEDLINE
4. 4 Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment. Hepatology 1998 ; 27: 1443–1444. MEDLINE
5. 5 Di Bisceglie A. Hepatitis C and hepatocellular carcinoma. Hepatology 1997 ; 26 (Suppl 1): 3S–38S.
6. 6 Schalm S, Fattovitch G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997 ; 26 (Suppl 1): 128S–132S. MEDLINE
7. 7 Farmachidi JP, Rufat P, Vilgrain V, Njapoum C, Valla D, Marcellin P, Erlinger S, et al. Long‐term course and pronostic factors in hepatitis C virus‐related compensated cirrhosis. J Hepatol 1998 ; 28 (Suppl 1): S80.
8. 8 Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of chronic hepatitis C. Hepatology 1997 ; 26 (Suppl 1): 122S–127S. MEDLINE
9. 9 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomized trial of effects of interferon‐α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 ; 346: 1051–1055. MEDLINE
10. 10 Knodell RG, Ishak K, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 ; 1: 431–435. MEDLINE
11. 11 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. for the French METAVIR cooperative study group Hepatology 1996 ; 24: 289–293. MEDLINE
12. 12 Jimenez W, Pares A, Caballeria J, Heredia J, Gruguera M, Torres M, Rojkind M, et al. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology 1985 ; 5: 815–818. MEDLINE
13. 13 Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trépo C, Grimaud JA. Interferon‐α 2b therapy reduces liver fibrosis in chronic non‐A non‐B hepatitis: a quantitative histological evaluation. Hepatology 1993 ; 18: 1344–1349. MEDLINE
14. 14 Duchatelle V, Marcellin P, Giostra E, Pouteau M, Auperin A, Guerret S, Molas G, et al. Changes in liver fibrosis at the end and 6 to 18 months after interferon therapy in patients with chronic hepatitis C: a quantitative assessment by a morphometric method. J Hepatol 1998 ; 29: 20–28. MEDLINE
15. 15 Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long‐term histologic improvement and loss of detectable intrahepatic hepatitis C virus RNA in patients with chronic hepatitis C and sustained response to interferon‐α therapy. Ann Intern Med 1997 ; 127: 875–881. MEDLINE
16. 16 Chossegros P, Chevallier M, Guerret S, Trépo C, Grimaud JA. Long‐term administration of interferon‐α limits progression of liver fibrosis in non‐responder patients with chronic hepatitis C. J Hepatol 1994 ; 21 (Suppl 1): S62.
17. 17 Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alpha‐2b regimens for the long term treatment of chronic non‐A, non‐B hepatitis. N Engl J Med 1995 ; 332: 1457–1462. MEDLINE
18. 18 Rémy AJ, Tanguy G, Daurès JP, Blanc P, Larrey D. Qualité de vie dans l'hépatite chronique virale C: premières données françaises chez 100 malades. Apport d'un indicateur spécifique sur un indicateur général. Gastroenterol Clin Biol 1998 ; 22: A49.
19. 19 Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical encephalopathy in apparently healthy, ambulant, non‐shunted patients with cirrhosis. J Hepatol 1986 ; 3: 75–82. MEDLINE
20. 20 Sieck JO, Ellis ME, Alfurayh O, Ali MA, Ali HA, Ayub A, Al‐Fadda M, et al. Histologically advanced chronic active hepatitis treated with recombinant α‐interferon: a randomized placebo‐controlled double‐blind cross‐over study. J Hepatol 1993 ; 19: 418–423. MEDLINE
21. 21 Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, Nakamura T, et al. A randomized controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis. Am J Gastroenterol 1994 ; 89: 681–686. MEDLINE
22. 22 Jouet P, Roudot‐Thoraval F, Dhumeaux D, Métreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non‐A, non‐B, C hepatitis. le groupe français pour l'étude du traitement des hépatites chroniques NANB/C. Gastroenterology 1994 ; 106: 686–690. MEDLINE
23. 23 Farell G, Cooksley WG, Dudley FJ, Watson K. Efficacy and tolerance of a 6‐month treatment course of daily interferon‐alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group. J Viral Hepat 1997 ; 4: 317–323. MEDLINE
24. 24 Carithers RL, Emerson SS. Therapy of hepatitis C: meta‐analysis of interferon alfa‐2b trials. Hepatology 1997 ; 26 (Suppl 1): 83S–88S. MEDLINE
25. 25 Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver diseases. Effects of interferon alfa therapy. N Engl J Med 1991 ; 324: 933–940. MEDLINE
26. 26 Mazzella E, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Noveili V, et al. α interferon treatment may prevent hepatocellular carcinoma in hepatitis C virus–related cirrhosis. J Hepatol 1996 ; 24: 141–147. MEDLINE
27. 27 Fattovitch G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow‐up study of 384 patients. Gastroenterology 1997 ; 112: 463–472. MEDLINE
28. 28 International interferon‐α hepatocellular carcinoma study group.Effect of interferon‐α on progression of cirrhosis to hepatocellular carcinomaù: a retrospective cohort study. Lancet 1998 ; 351: 1535–1539. MEDLINE
29. 29 Serfaty L, Aumaïtre H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus–related cirrhosis. Hepatology 1998 ; 27: 1435–1440. MEDLINE
30. 30 Kasahara A, Hayashi N, Moshizuki K, Takayanagi M, Yishioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998 ; 27: 1394–1402. MEDLINE